Omentin-1 vs BYM338
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | BYM338 |
|---|---|---|
| Category | Diabetes & Metabolic | Muscle & Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Bimagrumab (BYM338) |
| Molecular Weight | ~35 kDa | ~148 kDa |
| Half-Life | hours | ~2-3 weeks |
| Amino Acids | 313 | N/A |
| Typical Dose | No approved human dose; research use only | 10-30 mg/kg IV in trials |
| Route | IV|SC | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 140 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Omentin-1 Dosing
not established|not established
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.